98%
921
2 minutes
20
Background: This paper reconstructs and analyses the "official drug narratives" in Singapore and the Philippines as recounted by its drug enforcement agencies and government officials. Drawing inspiration from narrative analyses and works that have explored official and institutional narratives, it defines such narratives as government accounts of how drugs figured in its country's history and how it responded to the challenges posed by drugs to society. It then identifies common elements in these narratives, namely plot, settings, characters, and moral of the story.
Methods: Documents and other material from drug-policy and-enforcement related institutions, primarily the Central Narcotics Bureau (CNB) and the Ministry of Home Affairs (MHA) for Singapore, and the Dangerous Drugs Board (DDB) and Philippine Drug Enforcement Agency (PDEA) for the Philippines, from 2015 to 2024, with particularly attention to drug policy-related anniversaries and official commemorations.
Findings: In both countries, official drug narratives highlight the national(list) character of their drug policies and cast their longstanding campaigns in existential terms, relying on the language of statistics and expertise, as well as a curation of the past, to legitimise the righteousness of their initiatives. While people involved with drugs were the expected 'villains' and the citizenry, especially the youth, the expected victims, notable was the characterisation of drug enforcers as underdogs pit against powerful enemies.
Conclusion: Analysing official drug narratives offers a way to examine a country's policy trajectories and overall paradigms and call attention to aspects that may be overlooked because they are not directly related to policy. By reconstructing the narrative content and structure of governments' discourses on drugs, official drug narratives can contribute towards a better understanding not just of the making of national drug policies, but on the stories on which they stand.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drugpo.2025.104947 | DOI Listing |
Rev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
JACC Asia
August 2025
Division of Cardiology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea; CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea. Electronic address:
Background: Following percutaneous coronary intervention (PCI), the "no-reflow phenomenon" is associated with a worse outcome. However, it remains unclear how to prevent and treat this phenomenon during PCI.
Objectives: This study aimed to evaluate the association between thrombogenicity profiles and "no-reflow phenomenon" during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI).
Zhonghua Kou Qiang Yi Xue Za Zhi
September 2025
Harbin Medical University, Harbin 150081, China Department of Medical Genetics, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100006, China.
Rare diseases have become an issue of public health concern globally. In China, two rare disease lists have been released officially in 2018 and 2023, respectively. However, due to its importance in research, clinical management , therapeutic drug development and health security, we still need a clear definition of rare diseases in China.
View Article and Find Full Text PDFFront Pharmacol
August 2025
Department of Nursing, Gansu Health Vocational College, Lanzhou, China.
Introduction: Qiancao comprises five closely related species: L., Diels., Decne.
View Article and Find Full Text PDFJ Chromatogr B Analyt Technol Biomed Life Sci
August 2025
Academy of Forensic Science, Shanghai Key Laboratory of Forensic Medicine Shanghai Forensic Service Platform, Key Laboratory of Forensic Science, Ministry of Justice, Shanghai 200063, China.
Benzodiazepines and Z-drugs are commonly used as prescription medications to treat anxiety, epilepsy, insomnia, and alcohol withdrawal syndrome, but their use can lead to tolerance, dependence, and withdrawal reactions if taken against official guidelines. Furthermore, designer benzodiazepines, most of which lack clinical and toxicological data, have entered the illicit drug market as new psychoactive substances and are used for recreational purposes. Their abuse can cause confusion, memory loss, respiratory depression, and even death, especially when combined with other sedative-hypnotics or alcohol.
View Article and Find Full Text PDF